Analysis of the cytotoxic determinants for methotrexate (NSC 740)

a role for 'free' intracellular drug

Research output: Chapter in Book/Report/Conference proceedingChapter

59 Citations (Scopus)

Abstract

Therapeutic regimens which employ high dose methotrexate (MTX) infusions over long intervals are likely to create conditions in which cells are exposed to levels of intracellular MTX in considerable excess of the capacity of high affinity intracellular binding sites. This paper reviews experimental evidence which suggests that the ability of MTX to inhibit nucleic acid and protein synthesis may depend upon the accumulation of free intracellular MTX. The possibility is raised that this may be related to the association of a portion of this intracellular component with a form of dihydrofolate reductase with a reduced affinity for this agent. The therapeutic end points and cytotoxic determinants for MTX are contrasted for conditions in which binding to the target enzyme is stoichiometric versus binding to lower affinity target enzymes. In an accompanying paper, factors which control the intracellular MTX level in excess of the tightly bound fraction are explored, focusing in particular on the roles of membrane transport and cellular energy metabolism.

Original languageEnglish (US)
Title of host publicationCANCER CHEMOTHER.REP.
Pages51-61
Number of pages11
Volume6
Edition1
StatePublished - 1975
Externally publishedYes

Fingerprint

Methotrexate
Pharmaceutical Preparations
Tetrahydrofolate Dehydrogenase
Enzymes
Nucleic Acids
Energy Metabolism
Binding Sites
Membranes
Therapeutics
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Analysis of the cytotoxic determinants for methotrexate (NSC 740) : a role for 'free' intracellular drug. / Goldman, I. David.

CANCER CHEMOTHER.REP.. Vol. 6 1. ed. 1975. p. 51-61.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{aadba086fbee4bb98b94c2512a31f0a0,
title = "Analysis of the cytotoxic determinants for methotrexate (NSC 740): a role for 'free' intracellular drug",
abstract = "Therapeutic regimens which employ high dose methotrexate (MTX) infusions over long intervals are likely to create conditions in which cells are exposed to levels of intracellular MTX in considerable excess of the capacity of high affinity intracellular binding sites. This paper reviews experimental evidence which suggests that the ability of MTX to inhibit nucleic acid and protein synthesis may depend upon the accumulation of free intracellular MTX. The possibility is raised that this may be related to the association of a portion of this intracellular component with a form of dihydrofolate reductase with a reduced affinity for this agent. The therapeutic end points and cytotoxic determinants for MTX are contrasted for conditions in which binding to the target enzyme is stoichiometric versus binding to lower affinity target enzymes. In an accompanying paper, factors which control the intracellular MTX level in excess of the tightly bound fraction are explored, focusing in particular on the roles of membrane transport and cellular energy metabolism.",
author = "Goldman, {I. David}",
year = "1975",
language = "English (US)",
volume = "6",
pages = "51--61",
booktitle = "CANCER CHEMOTHER.REP.",
edition = "1",

}

TY - CHAP

T1 - Analysis of the cytotoxic determinants for methotrexate (NSC 740)

T2 - a role for 'free' intracellular drug

AU - Goldman, I. David

PY - 1975

Y1 - 1975

N2 - Therapeutic regimens which employ high dose methotrexate (MTX) infusions over long intervals are likely to create conditions in which cells are exposed to levels of intracellular MTX in considerable excess of the capacity of high affinity intracellular binding sites. This paper reviews experimental evidence which suggests that the ability of MTX to inhibit nucleic acid and protein synthesis may depend upon the accumulation of free intracellular MTX. The possibility is raised that this may be related to the association of a portion of this intracellular component with a form of dihydrofolate reductase with a reduced affinity for this agent. The therapeutic end points and cytotoxic determinants for MTX are contrasted for conditions in which binding to the target enzyme is stoichiometric versus binding to lower affinity target enzymes. In an accompanying paper, factors which control the intracellular MTX level in excess of the tightly bound fraction are explored, focusing in particular on the roles of membrane transport and cellular energy metabolism.

AB - Therapeutic regimens which employ high dose methotrexate (MTX) infusions over long intervals are likely to create conditions in which cells are exposed to levels of intracellular MTX in considerable excess of the capacity of high affinity intracellular binding sites. This paper reviews experimental evidence which suggests that the ability of MTX to inhibit nucleic acid and protein synthesis may depend upon the accumulation of free intracellular MTX. The possibility is raised that this may be related to the association of a portion of this intracellular component with a form of dihydrofolate reductase with a reduced affinity for this agent. The therapeutic end points and cytotoxic determinants for MTX are contrasted for conditions in which binding to the target enzyme is stoichiometric versus binding to lower affinity target enzymes. In an accompanying paper, factors which control the intracellular MTX level in excess of the tightly bound fraction are explored, focusing in particular on the roles of membrane transport and cellular energy metabolism.

UR - http://www.scopus.com/inward/record.url?scp=0016757278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016757278&partnerID=8YFLogxK

M3 - Chapter

VL - 6

SP - 51

EP - 61

BT - CANCER CHEMOTHER.REP.

ER -